部份中文多西他赛无水处方资料（仅供参考）
Nanoxel-M Inj（多西他赛无水注射）
商标名称：Nanoxel PM
通用名称：多西他赛
生产商：韩国 Samyang Biopharm
治疗类别：生物碱
描述
多西他赛胶束静脉制剂，Nanoxel-PM™采用基于聚合物的递送系统的开发，本品包含在无色透明的小瓶为白色或淡黄色粉末或多孔光硬块的冻干注射毒品。
使用融化。
成分
一小瓶Nanoxel中号注射液（500毫克）
多西紫杉醇无水..................................... 20毫克
一小瓶Nanoxel中号注射液（2000毫克）
多西紫杉醇无水..................................... 80毫克
临床适应症及用法
本品临床适应症为：卵巢癌、乳腺癌、非小细胞肺癌的一线和二线治疗；前列腺癌、胰腺癌、胃癌、食管癌、软组织肿瘤、头颈部肿瘤等的治疗。
临床推荐用氯化钠注射液溶解、稀释后，直接用于静脉滴注。
Nanoxel® M Inj
Product: Nanoxel PM
Generic Name:   docetaxel
Therapeutic Subcategory:     Alkaloids
Effcacy,Effecf
Breast cancer
Along with doxorubicin, Nanoxel is administered as a primary drug for locally progressed or metastatic breast cancer.
Along with trastuzumab, the drug is administered for metastatic breast cancer with the excessive manifestation of HER2
(human epidermal growth factor receptor 2 protein) and with no chemotherapy experience.
Locally progressed or metastatic breast cancer that the previous chemotherapy failed to arrest
Along with capecitabine, the drug is administered for locally progressed or metastatic breast cancer
that the administration of anthracycline drugs and that chemotherapy failed to arrest.
Along with doxorubicin and cyclophosphamide, the drug is administered as an adjuvant therapy after operation
for operable-lymph-node-positive breast cancer.
Non-small-cell lung cancer
Locally progressed or metastatic non-small-cell lung cancer, including cases that
the platinum chemotherapies failed to arrest
Prostate cancer
Along with prednisolone, the drug is administered for the treatment of androgen non-dependent (hormone-unresponsive)
metastatic prostate cancer.
Ovarian cancer
Along with carboplatin, the drug is administered as a primary drug for progressed
or metastatic epithelial ovarian cancer.
Head and neck cancer
Along with cisplatin and 5-fluorouracil is administered as an induction therapy for locally progressed
squamous-cell carcinoma in the head and neck.
Gastric cancer
Administered alone for progressive and metastatic or locally recurrent gastric cancer.
Together with cisplatin and 5-fluorouracil, the drug is administered as a primary drug for metastatic or locally recurrent gastric cancer.
Esophageal cancer
Progressive or recurrent esophageal squamous-cell carcinoma.
Description
A freeze-dried injection drug contained in a colorless and transparent vial as white or pale-yellow powder or porous light lumps.
Use melted.
lngredients
One-vial Nanoxel M Injection (500mg)
Docetaxel anhydrous..................................... 20mg
One-vial Nanoxel M Injection (2000mg)
Docetaxel anhydrous..................................... 80mg
usage,Dosage
75-100 mg/m2 should be intravenously injected for one hour every three weeks.
To minimize the serious hypersensitivity reaction and fluid retention that may be manifested during the administration of this drug, pretreatment should be performed. For the pretreatment, if not banned, for three days leading to one day before administering this drug, oral corticosteroid should be administered (for dexamethason, 16 mg each day — e.g., twice, with 8mg administered each time — should be administered). Thus, to ease the danger of haematological toxicity, G-CSF can be proactively administered.
In hormone-unresponsive, metastatic prostate cancer, if administered together with prednisone, it is recommended that as a pretreatment, 8mg oral dexamethasone be administered 12 hours, 3 hours, and 1 hour before the administration of this drug.
package。
1Vial